readthroughSign in
Nov 12, 2026Quarterly update

Eledon reports Q3 2026 results, Phase 3 LEGACY trial on track for year-end start

Eledon said its global Phase 3 kidney transplant trial of tegoprubart remains set to begin in the fourth quarter, alongside new islet cell IND clearance and Fast Track status.

Eledon Pharmaceuticals reported third quarter 2026 results on November 12, 2026, saying its global Phase 3 LEGACY trial in kidney transplantation remains on track to initiate by year end.1 The study is designed to enroll roughly 600 patients and test whether tegoprubart is non-inferior to tacrolimus at 52 weeks, using a combined measure of biopsy-proven acute rejection, graft loss, and death.1

In regulatory news, the FDA cleared an IND application for a company-sponsored registrational study of tegoprubart aimed at preventing rejection in islet cell transplants for type 1 diabetes patients.1 Separately, tegoprubart received FDA Fast Track designation for prevention of rejection in kidney transplantation.1

On the clinical data side, updated Phase 2 BESTOW extension results shown at the Transplantation Society's September 2026 congress showed tegoprubart patients kept a statistically significant kidney function advantage over tacrolimus through 24 months, with an eGFR gap of about 13 mL/min/1.73m2, and no biopsy-proven rejection events in the tegoprubart arm after six months, versus seven such events on tacrolimus.1

In islet cell transplantation, the University of Chicago Medicine Transplant Institute added three patients to its investigator-led study. Eledon said the expansion builds on prior results in which 12 treated patients reached full insulin independence and showed stable graft function out to 22 months, with no nephrotoxicity, hypertension, or neurotoxicity observed to date.1

On finances, Eledon reported cash, cash equivalents and short-term investments of $69.7 million as of September 30, 2026, down from $133.3 million at the end of 2025.1 The company said this is expected to fund operations into the second quarter of 2027.1 Net loss for the quarter was $3.9 million, compared with a $17.5 million loss in the same period of 2025, a shift Eledon attributed largely to a non-cash $17.0 million gain from changes in warrant liability value, versus a $0.6 million gain a year earlier.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.